PTAB Clears Path For Earlier Generic Zytiga Launch

Patent Trial and Appeal Board finds that the patent covering the blockbuster prostate cancer drug is unpatentable, which could allow generics to launch at-risk in October once they obtain FDA approval; at least 12 firms have pending ANDAs.

Johnson & Johnson could face generic competition for its blockbuster prostate cancer therapy Zytiga (abiraterone acetate) as early as October now that the composition and method of use patent covering the drug has been found unpatentable by the US Patent and Trademark Office's Patent Trial and Appeal Board.

On Jan. 17, the Board issued final written decisions in five inter partes review (IPR) cases challenging patent No. 8,822,438,...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Novartis Upbeat Even With Entresto Expiry Looming

17 Jul 2025

• By Kevin Grogan

Swiss major confident that new oncology drugs will fill revenue gap.

China Sentences Astellas Employee To 3.5 Years In Prison On Spy Charges

17 Jul 2025

• By Lisa Takagi

An employee of Astellas faces three and a half years in prison after sentencing by a court in China on espionage charges.

Regeneron Wins PCSK9 Court Battle Against Amgen

16 May 2025

• By Alaric DeArment

A federal court jury found Amgen liable for violating antitrust laws in allegedly preventing Praluent from competing against Repatha.

Which Firms Are Most Exposed To Prasad’s Possible Accelerated Approvals Clampdown?

09 May 2025

• By Andrew McConaghie

Vaccine and accelerated approvals are expected to face greater scrutiny under new CBER leader Vinay Prasad, but he has promised “no light switch change” to policy, giving some reassurance to companies whose share prices have been battered.